Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Simponi (golimumab) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorization: 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Simponi (golimumab).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Provider Name: _____ Specialty: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

Please check the boxes that apply:

□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____

Sig: _____

Drug 2: Name/Strength/Formulation: _____

Sig: _____

5– Diagnosis/Clinical Criteria

1. Does the member have diagnosis of one of the following? **AND**
   □ Rheumatoid Arthritis (RA)

   □ Psoriatic arthritis (PsA)

   □ Ankylosing Spondylitis (AS)

   □ Ulcerative Colitis (UC)

   □ Other: _____

2. Was there therapeutic failure on oral methotrexate? **AND**
   □ No □ Yes

3. Was there therapeutic failure to one of the preferred agents? (e.g. Enbrel, Humira) **AND**
   □ No □ Yes

4. If this is being used for Rheumatoid Arthritis (RA):
   a. Did the patient try and fail or have a contraindication, or adverse reaction to methotrexate alone and at least one other DMARD (sulfasalazine, hydroxychloroquine, minocycline)? **AND**
      □ No □ Yes

   b. Is Simponi being used as combination therapy with methotrexate?
      □ No □ Yes

5. If this is being used for Ulcerative Colitis (UC):
   a. Did the patient try and fail a compliant regimen of oral or rectal aminosalicylates (i.e., sulfasalazine or mesalamine) for two consecutive months? **AND**
      □ No □ Yes

   b. Did the patient try and fail a compliant regimen of oral corticosteroids (for moderate to severe CD) unless contraindicated, or intravenous corticosteroids (for severe and fulminant CD or failure to respond to oral corticosteroids)? **AND**
      □ No □ Yes

   c. Did the patient try and fail a compliant regimen of azathioprine or mercaptopurine for three consecutive months?
      □ No □ Yes

6 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**